Practical Guidance on Mental Health and Physician Burnout
Latest News
Immunotherapy Drug Keytruda Shows Promising Event-Free Survival Results For High-Risk Melanoma Patients When Used Before And After Surgery
Contributed by Dr. James Taylor, MD, MPH, a Medical Fellow at SurvivorNet. A new study of patients with high-risk melanoma shows using the immunotherapy agent pembrolizumab, also known as Keytruda, used before and after surgery reduces the risk of tumor recurrence. Immunotherapy given before surgery can help prime the immune system to fight off cancer […]
Learn More‘Practice Changing’ Trial Results Suggest Tagrisso Can Delay Recurrence of EGFR Mutated Lung Cancer
Contributed by Abigail Seaberg, writer at SurvivorNet. The drug Tagrisso is showing promise for lung cancer patients, yet again. Updated results from the phase III ADAURA study presented at the European Society for Medical Oncology (ESMO) Congress 2022 showed that AstraZeneca’s drug osimertinib, brand name Tagrisso, demonstrated more exciting results for lung cancer patients […]
Learn MoreDrug Enhertu Targets New Category of Her2-Low Metastatic Breast Cancer Patients
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. For oncologists across the country, including community practices, the new developments around categorizing breast cancer patients as HER2-low is starting to play out in practice. The drug enhertu was approved for patients previously considered HER2 negative, but in an important breakthrough, the drug has been approved by […]
Learn MoreImmunotherapy Drug Imfinzi Plus Chemotherapy Boosts Survival Rates In Metastatic Lung Cancer Patients: New Study
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. If you have stage four non-small cell lung cancer (NSCLC) there is a hopeful new treatment option that shows increased survival rates in patients. New trial results show that a short-course of the immunotherapy drug tremelimumab combined with the drug Imfinzi (also knowns as durvalumab) […]
Learn MoreStudies Indicate Lynparza Extends Life of Patients with Advanced Stage Ovarian Cancer
Contributed by Dr. Rodrigo C. Leão Edelmuth, MD, Medical Fellow at SurvivorNet. Good news for women with ovarian cancer has just emerged from the European Society for Medical Oncology (ESMO) Annual Meeting: positive long-term data from two phase III trials of Olaparib (brand name Lynparza) maintenance treatment in patients with newly diagnosed advanced (stages […]
Learn MoreMen with Prostate Cancer Are Asking Their Doctors About Rectal Spacers
For a lot of us who treat men with prostate cancer, there are preferred methods and pathways. But, regardless, some of us in the community are not offering a simple procedure that can significantly improve quality of life for these patients.
Learn MoreAddressing Disparities in Cancer: What Industry and Clinicians Can Do to Collaborate Effectively
As key players in the oncology community, industry and clinicians have the power to make tangible progress on key aspects on disparities, according to panelists at Survivornet’s 2022 Close the Gap conference.
Learn More‘This is a Period of Rapid Progress:’ Dr. Giovanni Caforio of Bristol-Myers Squibb on the Revolution in Immunotherapy Drugs for Treating Advanced Cancers
Every once in a while, we think there’s some value in giving the SN Connect audience a little taste of some very key players in the oncology system. A while back, SurvivorNet had the chance to sit down with Dr. Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb (BMS).
Learn More